Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Cremolini

Showing results (151-160 of 284) with videos related to

Pageof 29
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 20, 2020
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trialsMartin D Berger, Yan Ning, Sebastian Stintzing, et al.
European Journal of Cancer (Oxford, England : 1990)|April 18, 2022
Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case seriesEmilie Hafliger, Alessandra Boccaccino, Alexandra Lapeyre-Prost, et al.
Clinical Colorectal Cancer|April 3, 2018
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With RegorafenibMitsukuni Suenaga, Marta Schirripa, Shu Cao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2025
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory <i>KRAS</i> G12C Colorectal CancerFilippo Pietrantonio, Lisa Salvatore, Taito Esaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2017
A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/CetuximabMartin D Berger, Sebastian Stintzing, Volker Heinemann, et al.
The Oncologist|July 7, 2016
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal CancerRoberto Moretto, Chiara Cremolini, Daniele Rossini, et al.
Updates in Surgery|July 1, 2022
Pattern of recurrence and survival after D2 right colectomy for cancer: is there place for a routine more extended lymphadenectomy?Matteo Palmeri, Andrea Peri, Valentina Pucci, et al.
British Journal of Cancer|February 9, 2023
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' developmentRoberto Moretto, Marco Maria Germani, Mirella Giordano, et al.
Clinical Drug Investigation|June 17, 2024
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 TrialErika Martinelli, Davide Ciardiello, Giulia Martini, et al.
JCO Precision Oncology|October 5, 2023
Predictive Impact of <i>RNF43</i> Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable <i>BRAFV600E</i>-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or ChemotherapyRoberto Moretto, Marco Maria Germani, Javier Ros, et al.
Pageof 29

Showing results (151-160 of 284) with videos related to

Sort By:
Pageof 29
European Journal of Cancer (Oxford, England : 1990)|April 20, 2020
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trialsMartin D Berger, Yan Ning, Sebastian Stintzing, et al.
European Journal of Cancer (Oxford, England : 1990)|April 18, 2022
Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case seriesEmilie Hafliger, Alessandra Boccaccino, Alexandra Lapeyre-Prost, et al.
Clinical Colorectal Cancer|April 3, 2018
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With RegorafenibMitsukuni Suenaga, Marta Schirripa, Shu Cao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2025
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory <i>KRAS</i> G12C Colorectal CancerFilippo Pietrantonio, Lisa Salvatore, Taito Esaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2017
A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/CetuximabMartin D Berger, Sebastian Stintzing, Volker Heinemann, et al.
The Oncologist|July 7, 2016
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal CancerRoberto Moretto, Chiara Cremolini, Daniele Rossini, et al.
Updates in Surgery|July 1, 2022
Pattern of recurrence and survival after D2 right colectomy for cancer: is there place for a routine more extended lymphadenectomy?Matteo Palmeri, Andrea Peri, Valentina Pucci, et al.
British Journal of Cancer|February 9, 2023
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' developmentRoberto Moretto, Marco Maria Germani, Mirella Giordano, et al.
Clinical Drug Investigation|June 17, 2024
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 TrialErika Martinelli, Davide Ciardiello, Giulia Martini, et al.
JCO Precision Oncology|October 5, 2023
Predictive Impact of <i>RNF43</i> Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable <i>BRAFV600E</i>-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or ChemotherapyRoberto Moretto, Marco Maria Germani, Javier Ros, et al.
Pageof 29